filo/iStock via Getty Images Exact Sciences ( NASDAQ: EXAS ) is down ~28% in after-hours trading Tuesday after reducing its 2024 guidance and releasing Q3 financial results that missed on both lines . The company now sees full-year revenue at $2.73B-$2.
750B, down from $2.81B-$2.85B prior.
Consensus is $2.83M..